drugset
drugset / Trial / NCT03413124

Bioavailability Study of MGL-3196 Tablets Compared to Capsules

NCT03413124 ↗

Phase 1 Completed 16 enrolled Madrigal Pharmaceuticals, Inc. Celerion · collab
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare the pharmacokinetics of MGL-3196 capsules with MGL-3196 tablets in healthy male subjects and female subjects not of child-bearing potential.

Timeline

Start
2018-02-05
Primary completion
2018-02-17
Completion
2018-03-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Resmetirom Small molecule — —

Indications

No indication recorded.